Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Counsyl | RCV000674474 | SCV000799816 | likely pathogenic | Peroxisome biogenesis disorder 1A (Zellweger) | 2018-05-08 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001377626 | SCV001575008 | likely pathogenic | Zellweger spectrum disorders | 2022-03-19 | criteria provided, single submitter | clinical testing | In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. ClinVar contains an entry for this variant (Variation ID: 558237). Disruption of this splice site has been observed in individual(s) with Zellweger syndrome spectrum disorder (PMID: 21031596). This variant is not present in population databases (gnomAD no frequency). This sequence change affects a donor splice site in intron 2 of the PEX1 gene. It is expected to disrupt RNA splicing. Variants that disrupt the donor or acceptor splice site typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in PEX1 are known to be pathogenic (PMID: 9398847, 16086329, 16141001, 21031596, 26387595, 31831025). |
Fulgent Genetics, |
RCV002499189 | SCV002806949 | likely pathogenic | Peroxisome biogenesis disorder 1A (Zellweger); Heimler syndrome 1; Peroxisome biogenesis disorder 1B | 2022-05-02 | criteria provided, single submitter | clinical testing | |
Baylor Genetics | RCV003472170 | SCV004203375 | pathogenic | Heimler syndrome 1 | 2023-12-10 | criteria provided, single submitter | clinical testing | |
Natera, |
RCV001377626 | SCV002079352 | likely pathogenic | Zellweger spectrum disorders | 2020-09-21 | no assertion criteria provided | clinical testing |